ViroMed’s myocardial infarction therapy cleared for phase 2 trial

Published : Aug 1, 2016 - 14:07 Updated : Aug 1, 2016 - 14:07

◀ Back to List
More article by this Writer

[DISCLOSURE] ViroMed (084990) announced on Aug. 1 that its VM202RY has been approved to initiate phase 2 of its clinical trials. VM202RY is a medicine for acute myocardial infarction by directly injecting into the cardiac muscles of the coronary artery territory.

◀ Back to List
More article by this Writer

LATEST NEWS

>

S. Korea not to attend Sado mine memorial: foreign ministry
>

[Weekender] Korea's traditional sauce culture gains global recognition
>

[What to Play] Cozy songs to warm you up
>

Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
>

Gyeongju blends old with new
>

At Gwangcheonok, try North Korean-style sundae gukbap
>

Over 80,000 malicious calls made to Seoul call center since 2020
>

Trump picks ex-N. Korea policy official as his principal deputy national security adviser
>

BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
>

What you need to know about Adani's US bribery indictment